%0 Journal Article
%T Choice of first-line anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) based on the results of a systematic review and network meta-analysis
%A Urbanska, Edyta Maria
%J Precision Cancer Medicine
%D 2023
%B 2023
%9 
%! Choice of first-line anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) based on the results of a systematic review and network meta-analysis
%K 
%X 
%U https://pcm.amegroups.org/article/view/7703
%V 6
%P 
%@ 2617-2216